ClinicalTrials.gg
CompletedNCT01161563Updated Sep 6, 2013Results posted

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

A Phase 4 interventional study of Triptorelin pamoate and Leuprolide acetate in Prostate Cancer, sponsored by Watson Pharmaceuticals. Completed at 16 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-06.

Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
16th of 28
118 · median 120
Started
2010
with 1 other
Phase 4
6 of 28
none open now
Registered
8th of 28
by date

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 16th largest by enrollment, is one of 2 that started in 2010, is one of 6 in phase 4, and was the 8th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.

Read the detailed description

GnRH is given as an injection. Injections of GnRH can be uncomfortable, causing a feeling of burning or stinging. The uncomfortable feeling may be caused by differences in the types of GnRH and the site of the injection (under the skin of the abdomen, or into the muscle of the buttock or thigh).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • palliative treatment
  • prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients with a diagnosis of advanced prostate cancer for whom treatment with triptorelin pamoate or leuprolide acetate is indicated;
  • At least 18 years of age;
  • of at least 1 year;
  • Capable of completing the study questionnaires without assistance.

Exclusion criteria

Exclusion Criteria:

  • Patients for whom treatment with triptorelin pamoate or leuprolide acetate is ;
  • Known to triptorelin, leuprolide or any other GnRH or luteinizing hormone releasing hormone (LHRH) agonists, or GnRH or LHRH;
  • systemic disease or condition that would, in the investigator's opinion, lead to undue risk following administration of either triptorelin or leuprolide;
  • History of alcohol/drug abuse within the past year;
  • History of significant medical problems that may confound the outcome of this study;
  • Requires concomitant medications that may affect study assessments (e.g., topical medications used for pretreatment of injection site pain);
  • Participated in another drug study within 30 days
  • Judged by the investigator to be unsuitable for enrollment in this study for any reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Active comparator
    Leuprolide acetate

    Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area. Injection occurred either 6 months before or 6 months after injection of triptorelin pamoate suspension (Trelstar 22.5 mg) intramuscularly in the buttock.

    Drug: Leuprolide acetate

  • Active comparator
    Triptorelin pamoate

    Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock. Injection occurred either 6 months before or 6 months after injection of polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) subcutaneously in upper or mid-abdominal area.

    Drug: Triptorelin pamoate

Interventions

  • Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock

  • Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.

06

What researchers measure

Primary outcomes

  1. Patient Bother From Injection Site Burning and/or Stinging

    Questionnaire responses recorded on a Visual Analog Scale (VAS), which has a range of 0-100 mm, assessed approximately 15 minutes post-injection

    Time frame: 15 minutes

Secondary outcomes

  1. Discomfort From Injection

    Questionnaire responses recorded on a Visual Analog Scale (VAS), which has a range of 0-100 mm, assessed approximately 15 minutes post-injection

    Time frame: 15 minutes

07

Results

Posted Sep 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneTriptorelin First, Then Leuprolide AcetateLeuprolide Acetate First, Then Triptorelin
Started6355
Completed5849
Not completed56

Outcome measures

PrimaryPatient Bother From Injection Site Burning and/or Stinging

Questionnaire responses recorded on a Visual Analog Scale (VAS), which has a range of 0-100 mm, assessed approximately 15 minutes post-injection

Time frame:
15 minutes
Reported as:
Mean · units on a scale
Patient Bother From Injection Site Burning and/or Stinging
units on a scaleLeuprolide AcetateTriptorelin Pamoate
Patient Bother From Injection Site Burning and/or Stinging23.87 (19.98 to 27.76)5.84 (1.95 to 9.73)
SecondaryDiscomfort From Injection

Questionnaire responses recorded on a Visual Analog Scale (VAS), which has a range of 0-100 mm, assessed approximately 15 minutes post-injection

Time frame:
15 minutes
Reported as:
Mean · units on a scale
Discomfort From Injection
units on a scaleLeuprolide AcetateTriptorelin Pamoate
Discomfort From Injection20.53 (16.49 to 24.56)5.88 (1.85 to 9.92)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate—0/118 (0%)0/118 (0%)
Triptorelin Pamoate—0/118 (0%)0/118 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Leuprolide Acetate First, Then TriptorelinTriptorelin First, Then Leuprolide AcetateTotal
<=18 years000
Between 18 and 65 years121729
>=65 years434689
Age Continuous
Age Continuous(years)Leuprolide Acetate First, Then TriptorelinTriptorelin First, Then Leuprolide AcetateTotal
Mean75.0 ± 9.673.2 ± 9.674 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate First, Then TriptorelinTriptorelin First, Then Leuprolide AcetateTotal
Female000
Male5563118
Region of Enrollment
Region of Enrollment(participants)Leuprolide Acetate First, Then TriptorelinTriptorelin First, Then Leuprolide AcetateTotal
United States5563118
08

Study locations

16 sites
  • Watson Investigational Site
    Homewood, Alabama, United States
  • Watson Investigational Site
    Daytona Beach, Florida, United States
  • Watson Investigational Site
    Orange City, Florida, United States
  • Watson Investigational Site
    Coeur D'Alene, Idaho, United States
  • Watson Investigational Site
    Carmel, Indiana, United States
  • Watson Investigational Site
    Jeffersonville, Indiana, United States
  • Watson Investigational Site
    Shreveport, Louisiana, United States
  • Watson Investigational Site
    Las Vegas, Nevada, United States
  • Watson Investigational Site
    Mt Laurel, New Jersey, United States
  • Watson Investigational Site
    Voorhees, New Jersey, United States
  • Watson Investigational Site
    Albany, New York, United States
  • Watson Investigational Site
    Syracuse, New York, United States
  • Watson Investigational Site
    Lancaster, Pennsylvania, United States
  • Watson Investigational Site
    Myrtle Beach, South Carolina, United States
  • Watson Investigational Site
    Dallas, Texas, United States
  • Watson Investigational Site
    Norfolk, Virginia, United States
09

References and documents

Publications

  • Shore ND, Sieber P, Schimke L, Perzin A, Olsen S. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer. Urol Nurs. 2013 Sep-Oct;33(5):236-44, 248. PubMed 24354113 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2010
First posted
Jul 13, 2010
Start
Jul 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Sep 6, 2013
Last update
Sep 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01161563
Responsible party
Sponsor
First posted
Jul 13, 2010
Start date
Jul 2010
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Sep 6, 2013
Last update
Sep 6, 2013

Study contacts

Marilyn McIlwain, BS
study director · Watson Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Triptorelin · Leuprolide

Start the discussion